| Jamie Brooke Peterson, PA-C | |
|
1325 Ne 7th St, Grants Pass, OR 97526-1358 | |
| (541) 460-5331 | |
| (541) 460-5165 |
| Full Name | Jamie Brooke Peterson |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 11 Years |
| Location | 1325 Ne 7th St, Grants Pass, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487078911 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | PA-1236 (Idaho) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Direct Orthopedic Care Llc | 2163648155 | 28 |
| Onepeak Southern Oregon Pc | 5395129670 | 23 |
News Archive
Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.
Accelerator Life Science Partners (Accelerator), a leading life science investment and management firm, today announced that it has launched Proniras Corporation, a company developing tezampanel for the treatment of a variety of seizure disorders.
"The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria approved an action plan Monday in response to recommendations made recently by the High-Level Independent Review Panel on Fiduciary Controls and Oversight Mechanism (HLP)," the Center for Global Health Policy's "Science Speaks" blog reports, adding, "The board stated that it accepts the underlying analysis made by the panel and that it 'presents a compelling case for a rapid and urgent transformation of the Global Fund.'"
Amgen today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jamie Brooke Peterson, PA-C 1325 Ne 7th St, Grants Pass, OR 97526-1358 Ph: (541) 460-5331 | Jamie Brooke Peterson, PA-C 1325 Ne 7th St, Grants Pass, OR 97526-1358 Ph: (541) 460-5331 |
News Archive
Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.
Accelerator Life Science Partners (Accelerator), a leading life science investment and management firm, today announced that it has launched Proniras Corporation, a company developing tezampanel for the treatment of a variety of seizure disorders.
"The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria approved an action plan Monday in response to recommendations made recently by the High-Level Independent Review Panel on Fiduciary Controls and Oversight Mechanism (HLP)," the Center for Global Health Policy's "Science Speaks" blog reports, adding, "The board stated that it accepts the underlying analysis made by the panel and that it 'presents a compelling case for a rapid and urgent transformation of the Global Fund.'"
Amgen today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab.
› Verified 5 days ago
Jordan Personius, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 500 Sw Ramsey Ave, Grants Pass, OR 97527 Phone: 541-789-4281 | |
Kailey R Kelly, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 500 Sw Ramsey Avenue, Grants Pass, OR 97527 Phone: 541-472-7000 | |
Mrs. Esther M Carson, PAC Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1309 Ne 6th St, Grants Pass, OR 97526 Phone: 541-479-3367 Fax: 541-479-0215 | |
Mrs. Kimberly L Waller, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1701 Nw Hawthorne Ave, Grants Pass, OR 97526 Phone: 541-471-3455 | |
Nolan Bastendorff, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 537 Union Ave Fl 2, Grants Pass, OR 97527 Phone: 541-507-2110 | |
Brian James Allen, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 702 Sw Ramsey Ave Ste 112, Grants Pass, OR 97527 Phone: 541-472-0603 Fax: 541-472-0609 | |
Mr. Benjamin Moss, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 495 Sw Ramsey Ave, Grants Pass, OR 97527 Phone: 541-476-6644 |